Advertisement

Physiological Roles of Ectoenzymes Indicated by the Use of Aminopeptidase Inhibitors

  • Fuminori Abe
  • Takaaki Aoyagi
Chapter

Abstract

In living organisms, enzymes work in complicated networks to perform various biological functions. To analyse such functions, specific enzyme inhibitors are needed. Such inhibitors would be of great value in elucidating disease processes and may have uses in the treatment of disease.

Keywords

Biological Response Modifier Lung Squamous Cell Carcinoma Cancer Immunol Squamous Cell Lung Cancer Adult Acute Myeloid Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abe, F., Shibuya, K., Uchida, M., Takahashi, K., Horinishi, H., Matsuda, A., Ishizuka, M., Takeuchi, T., and Umezawa, H., 1984, Effect of bestatin on syngeneic tumors in mice. Gann 75: 89–94.PubMedGoogle Scholar
  2. Abe, F., Shibuya, K., Ashizawa, J., Takahashi, K., Horinishi, H., Matsuda, A., Ishizuka, M., Takeuchi, T., and Umezawa, H., 1985, Enhancement of antitumor effect of cytotoxic agents by bestatin. J. Antibiot. 38: 411–414.PubMedCrossRefGoogle Scholar
  3. Abe, F., Hayashi, M., Horinishi, H., Matsuda, A., Ishizuka, M., Takeuchi, T., and Umezawa, H., 1986, Enhancement of a graft-versus-host reaction and delayed cutaneous hypersensitivity in mice by ubenimex. J. Antibiot. 39: 1172–1177.PubMedCrossRefGoogle Scholar
  4. Abe, F., Alvord, G., Koyama, M., Matsuda, A., and Talmadge, J. E., 1989a, Pharmacokinetics of bestatin and oral activity for treatment of experimental metastases. Cancer Immunol. Immunother. 28: 29–33.PubMedCrossRefGoogle Scholar
  5. Abe, F., Schneider, M., Black, P.L., and Talmadge, J.E., 1989b, Chemoimmunotherapy with cyclophosphamide and bestatin in experimental metastasis in mice. Cancer Immunol Immunother. 29: 231–236.PubMedCrossRefGoogle Scholar
  6. Abe, F., Matsuda, A., Schneider, M., and Talmadge, J.E., 1990a, Effect of bestatin on myelopoitic stem cells in normal and cyclophosphamide-treated mice. Cancer Immunol. Immunother. 32: 75–80.PubMedCrossRefGoogle Scholar
  7. Abe, F., Fujii, A., Yoshimura, K., Yugeta, E., Ishizuka, M., and Takeuchi, T., 1990b, hnmunomodulatory and therapeutic characteristics of bestatin (ubenimex). Int. J. Immunotherapy. 6: 203–209.Google Scholar
  8. Abo, T., 2001, Extrathymic pathway of T-cell differentiation and immunomodulation. Int. Immunopharmacol 1: 1262–1274.Google Scholar
  9. Amoscato, A.A., Balasubramaniam, A. and Alexander, J.W., 1988, Degradation of thymopentin by human lymphocytes: evidence for aminopeptidase activity. Biochim. Biophys. Acta. 955: 164–174.PubMedCrossRefGoogle Scholar
  10. Aoyagi K. et al 1992, Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection. J. Antibiot. 45: 1778–1784.PubMedCrossRefGoogle Scholar
  11. Aoyagi, T. and Umezawa H., 1975, Structures and activities of protease inhibitors of microbial origin. In: Proteases and Biological Control (Reich E, Rifkin D, Shaw E, eds.), Cold Spring Harbor Laboratory, Boston, pp. 429–454.Google Scholar
  12. Aoyagi, T., Suda, H., Nagai, M., Ogawa, K., Suzuki, J., Takeuchi, T., and Umezawa, H., 1976, Aminopeptidase activities on the surface of mammalian cells. Biochim. Biophys. Acta. 452: 131–43.PubMedCrossRefGoogle Scholar
  13. Aoyagi, T., Ishizuka, M., Takeuchi, T., and Umezawa, H., 1977, Enzyme inhibitors in relation to cancer therapy. Jap J Antibiot.(Suppl) 30 -S: 121–132.Google Scholar
  14. Aoyagi, T., Nagai, M., Iwabuchi, M., Liaw, W.S., Andoh, T., and Umezawa, H., 1978, Aminopeptidase activities on the surface of mammalian cells. Cancer Res. 38: 3505–3508.PubMedGoogle Scholar
  15. Aoyagi, T., Wada, T., Yamamoto, K., Kojima, F., Nagai, M., Harada, S., and Umezawa, H., 1984a, Different enzymatic oscillations in vivo caused by the stereoisomers of an aminopeptidase inhibitor, bestatin. J. Appl. Biochem. 6: 212–221.PubMedGoogle Scholar
  16. Aoyagi, T., Wada, T., Ohuchi, S., Kojima, F., Nagai, M., Kawahara, F., and Umezawa, H., 1984b, Oscillation of enzyme networks in spleen triggered by an immunopotentiator, bestatin. Biochem International. 9: 405–411.Google Scholar
  17. Aoyagi, T,. 1990, Small molecular protease inhibitors and their biological effects. In: Biochemistry of Peptide Antibiotics (Kleinkauf H, Dohren H, eds.), Walter de Gruyter, Berlin, New York, pp. 311–363.Google Scholar
  18. Aoyagi, T., 1996, Physiological roles of ectoenzymes indicated by the use of aminopeptidase inhibitors. In Aminopeptidases (Taylor A, eds.), Springer, New York, Berlin, Tokyo, pp. 155–172.Google Scholar
  19. Asada, E., Mano, H., Yamada, A., Ino, K., Ishizuka, T., Goto, S., and Tomoda, Y., 1992, Prophylactic effect of bestatin on the onset of invasive mole - clinical and fundamental studies. Biotherapy. 5: 145–152.PubMedCrossRefGoogle Scholar
  20. Bausback, H.H., and Ward, P.E., 1986, Degradation of low molecular weight opioid peptides by vascular plasma membrane aminopeptidase M. Biochim. Biophys. Acta. 882: 437–444.PubMedCrossRefGoogle Scholar
  21. Bhagwat, S.V., Lahdenranta, J., Giordano, R., Arap, W., Pasqualini, R,. and Shapiro, L.H., 2001, CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood, 97: 652–659.PubMedCrossRefGoogle Scholar
  22. Bierman, P.J., Abe, F., Buyukberber. S., Ino, K.., and Talmadge, J.E., 2000, Partial review of immunotherapeutic pharmacology in stem cell transplantation. In vivo. 14: 221–236.PubMedGoogle Scholar
  23. Blazsek, 1., Comisso, M., and Misset, J.L., 1991, Modulation of bone marrow cell functions in vitro by bestatin (ubenimex), Biomed. Pharmacother. 45: 81–86.PubMedCrossRefGoogle Scholar
  24. Blomgren, H., Esposti, P.L, Naslund, 1., Johansen, L., and Lemming, O., 1990, Adjuvant bestatin (ubenimex) treatment following full-dose local irradiation for bladder carcinoma. Acta Oncologica. 29: 809.PubMedCrossRefGoogle Scholar
  25. Bourinbaiar, A.S., Lee-Huang, S., Krasinski, K., and Borkowsky, W., 1994, Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro. Biomed. Pharmacother. 48: 55–61.PubMedCrossRefGoogle Scholar
  26. Bruley-Rosset, M., Florentin, 1., Kiger, N., Schuiz, J., and Mathe, G., 1979, Restoration of impaired immune functions of aged animals by chronic bestatin treatment. Immunology. 38: 75–83.PubMedGoogle Scholar
  27. Cadel, S., Foulon, T., Viron, A., Balogh, A., Midol-Monnet, S., Noel, N., and Cohen, P, 1997, Aminopeptidase B from the rat testis is a bifunctional enzyme structurally related to leukotriene-A4 hydrolase. Proc. Natl. Acad. Sci. USA. 94: 2963–2968.PubMedCrossRefGoogle Scholar
  28. Constam, D.B., Tabler, A.R., Rensing-Ehl, A., Kemler, I., Hersh, L.B., and Fontana A., 1995, Puromycin-sensitive aminopeptidase. Sequence analysis, expression, and functional characterization. J. Biol. Chem. 270: 26931–26939.PubMedCrossRefGoogle Scholar
  29. Dickneite, G., Kaspereit, F., and Sedlacek, H. H., 1984, Stimulation of cell-mediated immunity by bestatin correlates with reduction of bacterial persistence in experimental chronic Salmonella typhimurium infection. Infect. Immun. 44: 168–174.PubMedGoogle Scholar
  30. Dong, X., An, B., Kierstead, LP., Storkus, W.J., Amoscato, A.A., and Salter, R.D., 2000, Modification of the amino terminals of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells. J. Immunol. 164: 129–135.PubMedGoogle Scholar
  31. Ebihara, K., Abe, P., Yamashita, T., Shibuya, K., Hayashi, E., Takahashi, K., Horinishi, H., Enomoto, M., Ishizuka, M., and Umezawa, H., 1986, The effect of ubenimex on N-methyl-N-nitro-N- nitrosoguanidine-induced stomach tumor in rats. J. Antibiot. 39: 966– 970.PubMedCrossRefGoogle Scholar
  32. Ezawa, K., Minato, K., and Dobashi, K., 1996, Induction of apoptosis by ubenimex (bestatin) in human non-small-cell lung cancer cell lines. Biomed. Phrmacother. 50: 283–289.CrossRefGoogle Scholar
  33. Fujii, H., Nakajima, M., Saiki, I., Yoneda, J., Azuma, I., and Tsuruo T., 1995, Human melanoma invasion and metastasis enhancement by high expression of aminopeptidase N/CD13. Clin.Exp. Metastasis. 13: 337–344.PubMedCrossRefGoogle Scholar
  34. Fujisaki, T., Otsuka, T., Takamatsu, Y., Eto, T., Harada, M., and Niho, Y., 1995, Effects of bestatin on hematopoiesis in long-term human bone marrow cultures. Biomed. Pharmacother. 49: 69–74.PubMedCrossRefGoogle Scholar
  35. Furuse, K., Fukuoka, M., Genka, K., Kato, H., Tsubura, E., Ohta, M., Nakai, M., Kinuwaki, E., Nakano, M., and Ishikawa, S., 1993, Double blind controlled study of ubenimex (bestatin) against squamous cell lung cancer a multicentre cooperative study. Gan To Kagaku Ryoho. 20: 1187–1194.PubMedGoogle Scholar
  36. Hadden, J.W., Renoux, G., and Chirigos, M., 1990, The characterization of immunotherapeutic agents. Immunopharmac. Reviews. 1: 1–64.Google Scholar
  37. Harada, Y., Kajiki, A., Higuchi, K., Ishibashi, T., and Takamoto, M., 1983, The mode of immunopotentiating action of bestatin: enhanced resistance to Listeria monocytogenes infection. J. Antibiot. 36: 1411–1414.PubMedCrossRefGoogle Scholar
  38. Hashida, H., Takebayashi, A., Kanai, M., Adachi, M., Kondo, K., Kohno, N., Yamaoka Y., and Miyake M., 2001, Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. in press.Google Scholar
  39. Helene, A., Beaumont, A., and Roques, B.P., 1991, Functional residues at the active site of aminopeptidase N. Eur. J. Biochem. 196: 385–393.Google Scholar
  40. Hegde, S.P., Zhao, JF, Ashmun, R.A., and Shapiro, L.H., 1999, c-Maf induces monocytic differentiation and apoptosis in bipotent myeloid progenitors.Blood, 94: 1578–1589.PubMedGoogle Scholar
  41. Hersh LB., 1985, Characterization of membrane bound aminopeptidases from rat brain: identification of the enkephalin degrading aminopeptidase. J. Neurochem. 44: 1427–1435.PubMedCrossRefGoogle Scholar
  42. Hiraoka, A., Shibata, H., and Masaoka, T., 1992, Study Group of Ubenimex for BMT, hnmunopotentiation with ubenimex for prevention of leukemia relapse after allogeneic BMT, Transplant. Proc. 24: 3047–3050.Google Scholar
  43. Ikeda, S., Miyasato, M, Saito, K., NaKoyama, H., and Tajima, K., 1981, Phase I study of bestatin (II) In Small Molecular Immunomodifìers of Microbial Origin (Umezawa, H., eds.), Japan Scientific Societies Press, Tokyo, pp. 143–158.Google Scholar
  44. Ikeda, S., and Ishihara, K., 1986, Randomized, controlled study of bestatin in the treatment of Stage lb and II malignant melanoma. Int. J. Immunother. 2: 73–83.Google Scholar
  45. Ino, K., Goto, S., Okamoto, T., Nomura, S., Nawa, A., Isobe, K., Mizutani, S., and Tomoda Y., 1994, Expression of aminopeptidase N on human choriocarcinoma cells and cell growth suppression by the inhibition of aminopeptidase N activity. Jpn. J. Cancer Res. 85: 927–933.PubMedCrossRefGoogle Scholar
  46. Ino, K., Bierman, P.J., Varney, M.L., Heimann, D.G., Kaszynski, C.A., Walker, S.A., and Talmadge, JE., 1996, Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation. Cancer Immunol. Immunother. 43: 206–212.PubMedCrossRefGoogle Scholar
  47. Inoue, K., Sugiyama, H., and Osawa, H., 1994, WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 84: 3071–79.PubMedGoogle Scholar
  48. Inoue, T., Kanziak, H., Imak,i K., Narukawa, S., Higuchi, T., Katsuragawa, H., Maeda, M., and Mori, T., 1994, Bestatin, a potent aminopeptidase-N inhibitor, inhibits invitro decidualization of human endometrial stromal cells. J. Clin. Endocrinol. Metabo. 79,171–175.CrossRefGoogle Scholar
  49. Ishizuka, M., Masuda, T., Kanbayashi, N., Fukazawa, S., Takeuchi, T., Aoyagi, T., and Umezawa, H., 1980, Effect of Bestatin on mouse immune system and experimental murine tumors. J. Antibiot. 33: 642–652.PubMedCrossRefGoogle Scholar
  50. Ishizuka, M., Aoyagi, T., Takeuchi, T., and Umezawa, H., 1981, Activity of Bestatin: Enhancement of immune responses and antitumor effect, In Small Molecular Immunomodifìers of Microbial Origin-Fundamental and Clinical Studies of Bestatin (Umezawa, H. eds.), Japan Scientific Societies Press, Tokyo, pp. 17–38.Google Scholar
  51. Kehlen, A., Langner, J., and Riemann, D., 2000, Transforming growth factor-beta increases the expression of aminopeptidase N/CD13 mRNA and protein in monocytes and monocytic cell lines. Adv. Exp. Med. Biol. 477: 49–56.PubMedCrossRefGoogle Scholar
  52. Kanayama, N., Kajiwara, Y., Goto, J., Maradny, E, Maehara, K., Andou, K., and Terao T., 1995, Inactivation of interleukin-8 by aminopeptidase N (CD13). J. Leuk. Biol.57: 129–134.Google Scholar
  53. Kato, H., Konaka, C., Tsuboi, M., Takizawa, T., Sakuma, A., Saijo, N., and Ohta, M., 2001, A randomized Phase III study comparing ubenimex (bestatin) versus placebo as postoperatove adjuvant treatment in patients with stage I squamous cell lung cancer. Proc. Am. Soc. Clin. Oncol 20: 307a.Google Scholar
  54. Kumamoto, Y., 1985, Clinical research of prevention of recurrence of superficial bladder cancer. Cooperative study of clinical efficacy of bleomycin intravesical instillation and bestatin. Hinyokiyo. 31: 1861–1873.Google Scholar
  55. Kobayashi, T., Miyawaki, M., Tanimoto, M., and Ohno, R., 1996, Randomized trial between behenyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. J. Clin. Oncol. 14: 204–213.PubMedGoogle Scholar
  56. Koya, T., Narita, J., Honda S., and Abo T., 1999, Immunomodulation induced by Ubenimex, an antibiotic inhibitor of aminopeptidases. Biomed. Res, 20: 161–167.Google Scholar
  57. Look, A.T., Ashmun, R.A., and Shapiro, L.H., 1989, Human myeloid plasma membrane glycoprotein CD 13 (gpl50) is identical to amilaslpeptidase N. J. Clin. Invest. 83: 299–307.CrossRefGoogle Scholar
  58. Majima, H., 1981, Phase I and preliminary phase II clinical trials of bestatin. In Small Molecular Immunomodifiers of Microbial Origin (Umezawa, H., eds.), Japan Scientific Societies Press, Tokyo, pp. 159–172.Google Scholar
  59. Mathe, G., 1996, Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy? Biomed. Pharmacother. 50: 473–479.PubMedCrossRefGoogle Scholar
  60. Miyake, H., Takeda, C., and Okuda, M., 1984, Adjuvant therapy with bestatin for squamos cell carcinoma of head and neck. Otologia. Fukuoka, 30: 1861–1871, 1984.Google Scholar
  61. Moller, E., 1996, Virus-induced autoimmunity in man. 2nd International Kyoto Life Science Symposium, abstract, 79.Google Scholar
  62. Muller, W.E., Schuster, D.K, Zahn, R.K., Maidhof, A., Layhausen, G., Falke, D., Koren, R., and Umezawa H., 1982, Properties and specificity of binding sites for the immunomodulator bestatin on the surface of mammalian cells. Int. J. Immunopharmacol. 4: 393–400.PubMedCrossRefGoogle Scholar
  63. Murata, M., Kubota, Y., Tanaka, T., Iida-Tanaka, K., Takahara, J., and Irino S., 1994, Effect of ubenimex on the proliferation and differentiation of U937 human histiocytic lymphoma cells. Leukemia, 8: 2188–2193.PubMedGoogle Scholar
  64. Nakamura, K., Fujiwara, H., and NaKoyama T., 1996, An aminopeptidase inhibitor; bestatin, enhances gonadotrophin-stimulated ovulation in mice. Human Reproduction 11: 1952–1957.PubMedCrossRefGoogle Scholar
  65. Nakanishi, T., Tamai, I., Takaki, A., and Tsuji, A., 2000, Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer. 88: 274–80.PubMedCrossRefGoogle Scholar
  66. Nishizawa, R., Saino, T., Takita, T., Suda, H., Aoyagi, T., and Umezawa, H.., 1977, Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B. J.Med.Chem. 20:510–515.PubMedCrossRefGoogle Scholar
  67. Noma, T., Klein, B., Cupissol, D., Yata, J., and Serrou B., 1984, Increased sensitivity of IL-2 dependent cultured T cells and enhancement of in vitro IL-2 production by human lymphocytes treated with bestatin. Int. J. Immunopharmac. 6: 87–92.CrossRefGoogle Scholar
  68. O’Connell, P.J., Gerkis, V., and d’Apice, A.J.F., 1991, Variable O-glycosilation of CD13 (aminopeptidase N). J. Biol Chem. 266: 4593–4597.PubMedGoogle Scholar
  69. Okamura, S., Omori, F., Haga, K., Baba H., Sugimachi, K., and Niho Y., 1990, Influence of bestatin on production of granulocyte-macrophage colony- stimulating factor from human peripheral blood mononuclear cells in vitro.Acta. Oncol. 29: 795–797.PubMedCrossRefGoogle Scholar
  70. Ota, K., Kurita A., Yamasa K., Masaoka T., Uzuka Y., and Ogawa. N., 1986, Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults, Cancer Immunol. Immunother, 23: 5–10.CrossRefGoogle Scholar
  71. Ota, K., 1991, Review of ubenimex (Bestatin): clinical research, Biomed. Pharmacother. 45: 55–63.CrossRefGoogle Scholar
  72. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta ,J., Sakamoto, M., Stryhn A., Ashmun, R.A., Shapiro, L.H., Arap, W., and Ruoslahti, E., 2000, Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60: 722–727.PubMedGoogle Scholar
  73. Pulido-Cejudo, G., Conway, B., Proulx, P., Brown, R., and Izaguirre. C.A., 1997, Bestatinmediated inhibition of leucine aminopeptidase may hinder HIV infection. Antiviral Res. 36: 167–177.PubMedCrossRefGoogle Scholar
  74. Rosenzwajg, M., Tailleux, L., and Gluckman, J.C., 2000, CD13/N-aminopeptidase is involved in the development of dendritic cells and macrophages from cord blood CD34+ cells. Blood. 95: 453–460.Google Scholar
  75. Saiki, l., Murata, J., Watanabe, K„ Fujii, H., Abe, F., and Azuma, I., 1989, Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro, Jap. J. Cancer Res. 80: 873–878.Google Scholar
  76. Saiki, 1., Fujii, H., Yoneda, J., Abe, F., Nakajima, M., Tsuruo, T., and Azuma, I., 1993, Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int. J. Cancer. 54: 137–143.PubMedCrossRefGoogle Scholar
  77. Saito, K., Miyasato, H., Tajima, K., and Dceda, S., 1981, Phase I study of bestatin (I) In Small Molecular Immunomodifiers of Microbial Origin (Umezawa, H., eds.), Japan Scientific Societies Press, Tokyo, pp. 133–141.Google Scholar
  78. Sako, M., Konishi, S., and Hosoi, T., 1996, Study on child HCV infection by IFN-a treatment, Annual Research Report of Osaka-city Resident Doctors, 24: 217–220.Google Scholar
  79. Sanderink, G.J., Artur, Y., and Siest, G., 1988, Human aminopeptidases: a review of the literature. J. Clin. Chem. Clin. Biochem. 26: 795–805.PubMedGoogle Scholar
  80. Sanderink, G.J., Artur, Y., and Schiele, F., 1988, Alanine aminopeptidase in serum: biological variations and reference limits. Clin. Chem. 34: 1422–1430.PubMedGoogle Scholar
  81. Sasaki, S., Fukushima, J., Hamajima, K., Ishii, N., Tsuji, T., Xin, K.Q., Mohri, H., and Okuda, K.. 1998, Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1. Clin. Exp. Immunol. 111: 30–35.PubMedCrossRefGoogle Scholar
  82. Schorlemmer, H.U., Bosslet, K., and Sedlacek, H. H., 1983, The ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononudear phagocytes. Cancer Res. 43:4148–4153.PubMedGoogle Scholar
  83. Schorlemmer, H.U., Bosslet, K., Dickneite, G., Luben, G., and Sedlacek, H. H, 1984, Studies on the mechanism of action of the immunomodulator bestatin in various screening test systems. Behnnglnst. Mitt. 74: 157–173.Google Scholar
  84. Scornik, O.A., and Botbol, V., 2001, Bestatin as an experimetal tool in mammals. Current Drug Metabol. 2: 67–85.CrossRefGoogle Scholar
  85. Sekine, K., Fujii, H., and Abe, F., 1999, Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia. 13: 729–734.PubMedCrossRefGoogle Scholar
  86. Sekine, K., Fujii, H., Abe, F., and Nishikaea, K., 2001, Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. Int. J. Cancer. in press.Google Scholar
  87. Shibuya, K., Hayashi, E., Abe, F., Takahashi, K., Horinishi, H., Ishizuka, M., Takeuchi, T., and Umezawa, H., 1987, Enhancement of interleukin-1 and interleukin-2 release by ubenimex. J. Antibiot. 40: 363–369.PubMedCrossRefGoogle Scholar
  88. Shibuya, K., Chiba, S., Hino, M., Kitamura, T., Miyagawa, K., Takaku, F., and Miyazano, K., 1991, Enhancing effect of ubenimex (Bestatin) on proliferation and differentiation of hematopoietic progenitor cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation. Biomed. Pharmacother. 45: 71–80.PubMedCrossRefGoogle Scholar
  89. Talmadge, J. E., Lenz, B. F., Pennington, R., Long, C., Phillips, H., Schneider.M., and Tribble, H., 1986, Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res. 46: 4505–4510.PubMedGoogle Scholar
  90. Talmadge, J.E., Pelus, L.M., Black, P.L., and Abe, F., 1991, Hematological and therapeutic properties of bestatin in normal and myelosuppressed mice. Biomed. Pharmacother. 45: 61–69.PubMedCrossRefGoogle Scholar
  91. Talmadge, J.E., Ino, K., and Bieman, P.J., 1996, Bestatin for anticancer treatments. In ImmunoPharmaceuticals (Kimball ES. Eds.), CRC Press Inc., BocaRaton, pp. 135–158.Google Scholar
  92. Terui, Y., Ikeda, N., Tomizuka, H., Kasahara, T., Ohtsuki, T., Uwai, M., Itoh, M., Tanaka, M., Yamada, M., Shimamura, S., Ishizaka, Y., Dceda, K., Ozawa, K., Miura, Y., and Hatake, K., 1998, Activated endothelial cells induced apoptosis in leukemic cells by endothelial interleukin 8. Blood. 92: 2672–2680.PubMedGoogle Scholar
  93. Terui, Y., Tomizuka, H., Mishima, Y., Ikeda, N., Kasahara, T., Uwai, M., Mori, M., Itoh, M., Tanaka, M., Yamada, M., Shimamura, S., Ishizaka, Y, Ozawa, K.,. and Hatake, K., 1999, NH2-terminal pentapeptidase of endothelial interleukin 8 is responsible for the induction of apoptosis in leukemic cells and has an anti-tumor effect in vivo. Cancer Res. 59: 5651–5655.PubMedGoogle Scholar
  94. Tsunogake, S.,Takano, N., Enokihara, H., Furusawa, S., and Shishido, H., 1991, Differential effects of ubenimex on growth of normal human haematopoietic progenitors and leukemic cells. Int. J. Immunother. 7: 203–209.Google Scholar
  95. Tsunogake, S., Furusawa, S., Nagashima, S., Enokihara, H., Shishido, H., Fujii, H., and Abe, F., 1994, Effect of aminopeptidase inhibitors on the production of various cytokines by peripheral blood mononuclear cell and stromal cells and on stem cell factor gene expression in stromal cells: comparison of ubenimex with its stereoisomers. Int. J. Immunother. 10: 41–47.Google Scholar
  96. Ueda, T., Tohyama, K., Wano, Y., Tsutani, H., Fukushima, T., Iwasaki, H., Urasaki, Y., Gotoh, N., Kimura, S., Okamura, E., Kagawa, D., and Nakamura T., 1994, Pharmacokinetic and clinical pilot study of high-dose intermittent ubenimex treatment in patients with myelodysplastic syndrome. Anticancer Res. 14: 2093–2098.PubMedGoogle Scholar
  97. Umezawa H., 1972, Enzyme inhibitors of microbial origin. University of Tokyo Press, Tokyo, pp.1–114.Google Scholar
  98. Umezawa, H., Aoyagi, T., Suda, H., Hamada, M., amd Takeuchi T., 1976a, Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J. Antibiot. 29: 97–99.PubMedCrossRefGoogle Scholar
  99. Umezawa, II., Ishizuka, M., Aoyagi, T., and Takeuchi T., 1976b, Enhancement of delayed type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J. Antibiot. 29: 857–859.PubMedCrossRefGoogle Scholar
  100. Urabe, A., Mutoh, Y., Mizoguchi, H., Takaku, F., and Ogawa, N., 1993, Ubenimex in the treatment of acute nonlymphocytic leukemia in adults. Ann. Hematol. 67: 63–66.PubMedCrossRefGoogle Scholar
  101. Uzuka, Y., and Saito, Y., 1991, Bestatin treatment of myelodysplastic syndromes and chronic myelogenous leukemia. Biomed. Pharmacother. 45: 87–93.CrossRefGoogle Scholar
  102. van Hal, P.T,W, Hopstaken-Broos, J.P.M., Prins, A., Favalro, E.J., Huijibens, R.J.F.,Hilvering, C., Figdor, C.G., and Hoogsteden. H.C., 1994, Potential indirect antiinflammatory effects of IL4. J. Immunol. 153: 2718–2728.PubMedGoogle Scholar
  103. Wachsmuth, E.D., 1975, Aminopeptidase as a marker for macrophage differentiation. Exp.Cell Res. 96: 409–15.PubMedCrossRefGoogle Scholar
  104. Yamada, M., Sukenaga, Y., Fujii, H., Abe, F., and Takeuchi, T., 1994, Purification and characterization of a ubenimex (bestatin)-sensitive aminopeptidase B-like enzyme from K562 human chronic myeloid leukemia. FEBS Lett. 342: 53–56, 1994.PubMedCrossRefGoogle Scholar
  105. Yamashita, T., Ito, J., Abe, F., Takahashi, K., Takeuchi, T., and Enomoto, M., 1990,Autoradiographic study of tissue distribution of [3H]ubenimex in IMC carcinoma-bearing mice. Int. J. Immunopharmac. 12: 755–760.CrossRefGoogle Scholar
  106. Yeager, C.L., Ashumun, R.A, Williams, R.K., Cardellichio, C.B., Shapiro, L.H., Look, T.,and Holmes, K.V., 1992, Human aminopeptidase N is a receptor for human coronavirus 229E. Nature. 357: 420–422.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Fuminori Abe
    • 1
  • Takaaki Aoyagi
    • 2
  1. 1.Drug Research Department, R.& D. DivisionNippon Koyaku Co. Ltd.Kita-ku, TokyoJapan
  2. 2.Institute of Microbial ChemistryShinagawa-ku, TokyoJapan

Personalised recommendations